169 related articles for article (PubMed ID: 37695277)
1. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Katyal N; Halldorsdottir K; Govindarajan R; Shieh P; Muley S; Reyes P; Leung KK; Mullen J; Milani-Nejad S; Korb M; Goyal NA; Mozaffar T; Goyal N; Habib AA; Muppidi S
Muscle Nerve; 2023 Nov; 68(5):762-766. PubMed ID: 37695277
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Howard JF; Bril V; Vu T; Karam C; Peric S; De Bleecker JL; Murai H; Meisel A; Beydoun SR; Pasnoor M; Guglietta A; Van Hoorick B; Steeland S; T'joen C; Utsugisawa K; Verschuuren J; Mantegazza R;
Front Neurol; 2023; 14():1284444. PubMed ID: 38318236
[TBL] [Abstract][Full Text] [Related]
4. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
[TBL] [Abstract][Full Text] [Related]
5. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
[TBL] [Abstract][Full Text] [Related]
6. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
[TBL] [Abstract][Full Text] [Related]
7. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
Dos Santos JBR; Gomes RM; da Silva MRR
Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
9. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
Heo YA
CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
[TBL] [Abstract][Full Text] [Related]
10. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
Katyal N; Govindarajan R; Goyal N; Muley S; Muppidi S
Front Neurol; 2024; 15():1378080. PubMed ID: 38919970
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.
Horiuchi K; Nakamura S; Yamada K; Inoue T; Oiwa K
Neuromuscul Disord; 2024 Jun; 39():37-41. PubMed ID: 38772072
[TBL] [Abstract][Full Text] [Related]
12. Exacerbation of Thymoma-Associated Myasthenia Gravis Following Efgartigimod Treatment Related to Anti-acetylcholine Receptor Antibody Overshoot: A Report of Two Cases.
Kawama K; Warabi Y; Bokuda K; Kimura H; Takahashi K
Cureus; 2023 Dec; 15(12):e50692. PubMed ID: 38229781
[TBL] [Abstract][Full Text] [Related]
13. Efgartigimod in refractory autoimmune myasthenia gravis.
Remijn-Nelissen L; Tannemaat MR; Ruiter AM; Campman YJM; Verschuuren JJGM
Muscle Nerve; 2024 Jun; ():. PubMed ID: 38899431
[TBL] [Abstract][Full Text] [Related]
14. Real-World experience with efgartigimod in patients with myasthenia gravis.
Fuchs L; Shelly S; Vigiser I; Kolb H; Regev K; Schwartzmann Y; Vaknin-Dembinsky A; Dori A; Karni A
J Neurol; 2024 Jun; 271(6):3462-3470. PubMed ID: 38528163
[TBL] [Abstract][Full Text] [Related]
15. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
[TBL] [Abstract][Full Text] [Related]
16. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
17. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
Saccà F; Barnett C; Vu T; Peric S; Phillips GA; Zhao S; Qi CZ; Gelinas D; Chiroli S; Verschuuren JJGM
J Neurol; 2023 Apr; 270(4):2096-2105. PubMed ID: 36598575
[TBL] [Abstract][Full Text] [Related]
18. Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.
Frangiamore R; Rinaldi E; Vanoli F; Andreetta F; Ciusani E; Bonanno S; Maggi L; Gallone A; Colasuonno A; Tramacere I; Cheli M; Pinna A; Mantegazza R; Antozzi C
Eur J Neurol; 2024 Apr; 31(4):e16189. PubMed ID: 38164996
[TBL] [Abstract][Full Text] [Related]
19. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
20. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
